Journal
FOOD SCIENCE AND BIOTECHNOLOGY
Volume 27, Issue 3, Pages 853-857Publisher
KOREAN SOCIETY FOOD SCIENCE & TECHNOLOGY-KOSFOST
DOI: 10.1007/s10068-017-0296-7
Keywords
Lactobacillus gasseri BNR17; Irritable bowel syndrome; Probiotics
Categories
Funding
- Bio-Synergy Research Project of the National Research Foundation - Ministry of Science, ICT and Future Planning, Republic of Korea [2012M3A9C4048761]
Ask authors/readers for more resources
Lactobacillus gasseri BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect of Lb. gasseri BNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/m(2) were randomized to intake a placebo, low-dose (BNR-L, 2 x 10(8) CFU/day), intermediate-dose (BNR-M, 2 x 10(9) CFU/day), or high-dose BNR (BNR-H, 2 x 5 x 10(9) CFU/day) for four weeks. Questionnaire for IBS symptoms scores and Lb. gasseri BNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group. Lb. gasseri BNR17 was detected in all intake groups except placebo. In the preliminary study, Lb. gasseri BNR17 was confirmed to have probiotic properties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available